Petros Grivas, MD, PhD, on Update on Treatment With Sacituzumab Govitecan-hziy and Pembrolizumab in Urothelial Cancer

Posted: Wednesday, March 23, 2022

Petros Grivas, MD, PhD, of the University of Washington and Fred Hutchinson Cancer Research Center, discusses the potential role of sacituzumab govitecan-hziy in combination with pembrolizumab in patients with metastatic urothelial cancer who experienced disease progression after platinum-based regimens.